Whether exosome material follows a chemical peel or a dermaplaning session is the practitioner’s decision, and the published record gives that decision less to work with than it does for lasers or microneedling. No located study has paired vesicle material with a chemical peel or with dermaplaning, so the useful guide is the depth of the peel, the barrier it leaves behind, and the general periprocedural guidance that does exist [1, 2, 4].
This guide sets out the three peel depth classes and what reviewers report each one does to the skin, what laboratory work shows about dermaplaning, what consensus guidance says about the first topical step after a peel, and which vesicle studies sit closest. It closes with the gaps in the evidence and a documentation list a practice can use from the first session.
Regulatory position
The FDA stated in its 2019 public safety notification, still posted as of 9 November 2026, that there are currently no FDA-approved exosome products [20]. The agency also states that a product’s intended use, shown by its labeling and promotional claims, decides whether it is a cosmetic, a drug or both, which applies to peel products and to anything applied after them [18]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and peel selection, timing and patient selection are practitioner decisions this guide does not make.
Understanding peel depth as the variable that sets the barrier picture
Reviewers group chemical peels by how deep they reach. Castillo and Keri described superficial peels as reaching the epidermis to the papillary dermis, medium peels the papillary to upper reticular dermis, and deep peels the mid-reticular dermis, and Garelick and colleagues used the same three categories in a 2026 scoping review [4, 5].
The agent and its strength decide the class. Castillo and Keri listed salicylic acid at 5 to 30 percent, glycolic acid at 30 to 50 percent and Jessner’s solution among superficial peels, described trichloroacetic acid (TCA) as superficial, medium or deep depending on the concentration used, and placed phenol among deep peeling agents [4].
Depth matters in both directions. Lee and colleagues, writing for the International Peeling Society in 2019, stated that the depth of peels is directly related to improved results and to the number of complications that can occur [3], which is why the depth class belongs at the top of any record that also lists a material applied afterward.
Comparing peel classes and dermaplaning by the surface each leaves
The table places each class against the depth reviewers assign it, the histology reported after it and the vesicle studies located for it. Dermaplaning is included because practices often ask about it in the same breath, although it is a mechanical procedure and its evidence comes from laboratory work.
| Procedure | Agents named in the reviews | Depth reached | Histology or barrier finding reported | Vesicle studies located |
|---|---|---|---|---|
| Superficial peel | Salicylic acid 5 to 30%, glycolic acid 30 to 50%, Jessner’s solution, lower-strength TCA | Epidermis to papillary dermis | Epidermal necrosis followed by regeneration, with equivocal dermal change (13 studies, 142 participants) | None |
| Medium-depth peel | TCA at medium-depth concentrations | Papillary to upper reticular dermis | Mostly increased dermal thickness and collagen content (13 studies, 75 participants) | None |
| Deep peel | Phenol formulas; TCA at the highest concentrations | Mid-reticular dermis | Consistent, long-lasting epidermal and dermal thickening and collagen production (13 studies, 294 participants) | None |
| Dermaplaning | A blade drawn across the skin; no chemical agent | Stratum corneum and some viable epidermis, in a laboratory model | Loss of stratum corneum and a drop in electrical resistance, with variation between operators | None |
The depth column comes from Castillo and Keri, the histology column for the three peel classes from Bommareddy and colleagues in 2026, and the dermaplaning row from Tijani and colleagues in 2023. Bommareddy and colleagues noted that their samples were heterogeneous and that biopsy timing varied, so the histology describes a direction of change rather than a timetable [2, 4, 8].
Measuring barrier change after superficial and TCA peels
Barrier disruption after a peel can be measured, and the instruments are ordinary clinic tools. Cameli and colleagues tested pyruvic acid and TCA peels on the forearms of 20 volunteers in 2018 and recorded the stratum corneum by reflectance confocal microscopy, water loss by transepidermal water loss (TEWL) and hydration by corneometry at baseline, 10 minutes, 24 hours and one week [7].
That study also showed that the vehicle matters alongside the acid. The authors reported that the same acid concentration in a different solvent system produced less barrier alteration, water loss and redness [7], so two peels with the same label percentage may leave different surfaces for whatever follows.
Santhanam and colleagues measured barrier recovery by TEWL after an in-clinic 70 percent glycolic acid peel in a series of controlled studies published in 2025. Their topical product was a seaweed ferment serum made by the employer of three of the authors [6], so the study speaks to how recovery can be measured after a superficial peel and says nothing about vesicle material.
For exosomes after a TCA peel, the relevant point is the medium-depth row of the table. A TCA peel at medium-depth strength reaches the papillary to upper reticular dermis [4], and Garelick and colleagues noted that the peeling and redness after a chemical peel can last a few weeks before subsiding, depending on the strength and ingredients used [5], which makes it a different starting point from a light glycolic peel.
Understanding dermaplaning as a stratum corneum procedure
Dermaplaning removes surface skin with a blade, and the best data on what it removes come from pharmaceutical science. Tijani and colleagues applied four strokes of a dermaplane device in a 2023 laboratory study and reported histology showing removal of the stratum corneum and some viable epidermis, a significant drop in electrical resistance and raised permeation of two model drugs over 24 hours [8].
The same group compared dermaplaning with other physical methods in a second 2023 study. Every method shortened the lag time for a small molecule to cross the skin to about 3 to 12 minutes, from about 71 minutes without one, and dermaplaning delivered less in the first hour than sonophoresis or laser [9].
Two cautions follow from that work. Results varied between the people operating the device [8], and the molecules tested were far smaller than vesicles, so the studies show that dermaplaning thins the barrier without showing how far a particle the size of an exosome travels afterward.
The clinical evidence for dermaplaning itself is thin. Pryor and colleagues reviewed the literature in 2011 and concluded that the scientific data supporting dermaplaning, topical oxygen and light therapy were scarce, anecdotal and not well documented [10], and the located literature since then has added laboratory permeation studies rather than clinical trials.
Published guidance on the first topical step after a peel remains general
The most specific located guidance comes from a 2025 consensus of six Australian practitioners led by McDonald. The panel separated procedures that disrupt the barrier, including chemical peels, from those that do not, and stated that after chemical peeling it is commonplace and reasonable to use antioxidants, hyaluronic acid, aloe and calming botanicals [1].
The same panel named growth factors for the period immediately after needling procedures and did not extend that statement to peels. It also advised that makeup and skincare actives be avoided immediately after surface-active procedures, and observed that epidermal disruption may raise the penetration of applied agents for the following few days [1].
That consensus carries a level of evidence of 5, and its medical writing support was sponsored by a skincare company [1]. Read together with the absence of vesicle studies, it shows that no published source ranks exosome material, or any other biologic material, for the hours or days after a peel, and that timing after each depth class remains a clinical judgment.
Same-day dermaplaning and exosome material
No located study or consensus statement addresses applying vesicle material on the same day as dermaplaning. The laboratory data show the stratum corneum thinned and permeation raised for small molecules, which a practitioner can weigh alongside the material’s documentation and the patient’s skin type.
The vesicle evidence closest to a peel comes from other resurfacing procedures
The nearest controlled human study used a laser. Kwon and colleagues applied an adipose stem cell exosome gel just after each of three fractional CO2 laser sessions in a 2020 double-blind split-face trial of 25 adults, had patients rate erythema, swelling and dryness daily for seven days after each session, and reported milder erythema and shorter downtime on the exosome side [11].
A laser channel and a peeled surface differ in shape, since a fractional laser leaves columns of injury between intact skin while a peel acts across the whole surface. The Kwon trial therefore shows a design for studying vesicle material after a barrier-disrupting procedure, and its gels were made and supplied by their manufacturer, a disclosure the references carry [11].
Lin and colleagues pooled randomized trials of stem cell conditioned medium combined with resurfacing in a 2023 meta-analysis whose scope named laser, chemical peeling and microneedling. Conditioned medium is a different material class from isolated vesicles, and the published abstract does not say how many of the five included trials used a peel [13].
Two smaller studies describe vesicles on skin without a peel. Zhang and colleagues reported in 2024 that fluorescence-labeled small vesicles applied to skin explants localized in the stratum corneum [14], and Choi and colleagues reported in 2026 lower TEWL on the vesicle side of a 16-adult split-face trial that used ultrasound-assisted delivery, with funding from the material’s manufacturer [15].
Across the wider facial literature, Gaebe and colleagues reviewed 16 vesicle studies with 503 participants in 2026. They reported no serious adverse events in the included studies and rated the certainty of the evidence low or very low, with risk of bias moderate to critical [12].
Peel products sit on the line between cosmetic and drug
The FDA states that intended use decides whether a product is a cosmetic, a drug or both, and that claims to affect the structure or function of the body, such as claims to regenerate cells, make a product a drug [18]. That rule covers the peel solution and the material applied after it, which is why ExaVeyra describes its material by what it is and leaves the clinical purpose to the practitioner.
The agency’s page on alpha hydroxy acids describes products marketed as skin peelers, which may carry relatively high acid concentrations designed to remove the outer layer of skin. The FDA counted 114 adverse dermatologic reports for AHA skin care products from 1992 to February 2004 and stated that the more serious reactions were reported most often for the products causing the greatest exfoliation [19].
FDA research on the same page reported an 18 percent rise in sensitivity to UV reddening after four weeks of an AHA cream, and a week after use stopped the researchers found no significant difference in UV sensitivity [19]. Lardieri and colleagues at the FDA drug center identified 18 skin injuries after laypeople applied chemical peel products between 2018 and 2023, several with products labeled at concentrations typically used by healthcare professionals, and concluded that laypeople who apply these products without guidance from licensed, trained professionals may experience skin injury [17].
Understanding what the evidence does not yet show
The gaps here are wider than for lasers or microneedling, and each one is a study design waiting to be run. A practice that records its sessions carefully is already collecting the kind of data the literature lacks.
- No located published study or registered trial pairs vesicle material with a chemical peel of any depth or with dermaplaning; searches of PubMed and ClinicalTrials.gov repeated on 9 November 2026 returned no matching study.
- No study has measured how deep vesicles travel after a peel; the dermaplaning permeation data use molecules far smaller than vesicles, and the explant work by Zhang and colleagues used skin with no peel [8, 9, 14].
- The periprocedural consensus by McDonald and colleagues carries a level of evidence of 5 and does not mention vesicle material after peels [1].
- Peel histology is heterogeneous: Bommareddy and colleagues pooled studies with heterogeneous samples and varied biopsy timing [2].
- Darker skin types are underrepresented: Garelick and colleagues found seven qualifying studies in Fitzpatrick types IV to VI and advised caution with medium-to-deep peels in those types [5].
- Industry ties run through the nearest evidence: the Kwon and Choi materials came from their manufacturer, the Santhanam authors work for or consult to the serum’s maker, and the consensus writing support was company-sponsored [1, 6, 11, 15].
Documenting a peel or dermaplaning session that includes exosome material
A practice that records the fields the published studies report can compare its own results with the literature and answer an investigator’s or a regulator’s questions from one file. The list below follows the peel reviews, the barrier studies and the MISEV2023 reporting headings cited in this guide [16].
- The procedure: peel agent, concentration, vehicle, number of layers and contact time, or for dermaplaning the blade, number of passes and operator
- The depth class the practitioner assigns, read against the comparison table above
- The time from the end of the peel or dermaplaning to surface application of any material
- The material by name and class: exosomes, conditioned medium or another preparation
- The lot number and expiry, with the lot’s certificate of analysis and characterization panel requested and filed, mapped where possible to MISEV2023 headings
- The cold-chain record from receipt to use, and the time between thawing or reconstitution and application
- Fitzpatrick type, any priming regimen and pigmentary history
- Recovery endpoints: erythema, peeling, patient-reported downtime and photographs at fixed intervals, with TEWL where the practice has the instrument
- Any adverse event, with the lot number, and its report to the FDA through MedWatch [20]
Questions to ask a supplier
Which source cells and isolation method produced this lot? Does the certificate of analysis report particle size, concentration, positive and negative markers, sterility and pathogen testing? How is the material shipped and at what temperature, and does the record cover every leg? Which published study, if any, used the same material?
The peel literature is mature and the vesicle literature is growing quickly, and the study that joins them is a natural next step for practices that already keep careful records. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats; it ships frozen from the manufacturing facility, every vial carries its lot number, and a certificate of analysis is generated for every lot and available on request together with the characterization panel and cold-chain records. Every certificate reports serological testing for pathogens, and ExaVeyra’s miRNA characterization data is available on request, so a practice can document every session to the standard the best studies set.
Anyone can apply for an account or ask the scientific team a question without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing. Practices planning to document peel or dermaplaning sessions can apply today or send the scientific team a question about the lot documents. Product and brand names in the cited studies are trademarks of their respective owners.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.McDonald C, Yip L, Sullivan J, Liu W, Lin F, Goodman G. A Guide to Periprocedural Skin Care Regimen for Injectable and Nonenergy Cosmetic Procedures Based on a Consensus of 6 Aesthetic Practitioners. Aesthet Surg J Open Forum. 2025;7:ojaf121. PMID 41230112. PMC12602870. doi:10.1093/asjof/ojaf121Expert consensus of six Australian practitioners (five dermatologists, one plastic surgeon); level of evidence 5. Carries in this article: the split into barrier-disruptive and nondisruptive procedures; the statement that after chemical peeling it is commonplace and reasonable to use antioxidants, hyaluronic acid, aloe and calming botanical agents, and that hyaluronic acid and antioxidants may be used immediately after chemical peels, while growth factors were named for the period immediately after needling; the advice to avoid makeup and skincare actives immediately after surface-active procedures; and the note that epidermal disruption may raise penetration for a few days. Disclosure: medical writing support was sponsored by a skincare company, and the authors list industry consulting or advisory roles.
- 2.Bommareddy K, Brody H, Cheng S, Landau M, Lee K. Histologic Changes After Chemical Peeling: A Clinical Review. Dermatol Surg. 2026;52(5):453-457. PMID 41147724. doi:10.1097/DSS.0000000000004916Narrative clinical review of PubMed studies reporting epidermal and dermal histology after peeling. Carries in this article: thirteen studies (142 participants) after superficial peels describing epidermal necrosis with regeneration and equivocal dermal change; thirteen (75) after medium-depth peels describing mostly increased dermal thickness and collagen; thirteen (294) after deep peels describing consistent epidermal and dermal thickening and collagen production; the authors noted heterogeneous samples and biopsy timing. Disclosure: no conflict statement in the PubMed record.
- 3.Lee KC, Wambier CG, Soon SL, Sterling JB, Landau M, Rullan P, Brody HJ; International Peeling Society. Basic chemical peeling: Superficial and medium-depth peels. J Am Acad Dermatol. 2019;81(2):313-324. PMID 30550830. doi:10.1016/j.jaad.2018.10.079Continuing medical education review from members of the International Peeling Society. Carries in this article: the statement that the depth of peels is directly related to improved results and to the number of complications that can occur. Disclosure: no conflict statement in the PubMed record.
- 4.Castillo DE, Keri JE. Chemical peels in the treatment of acne: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:365-372. PMID 30038512. PMC6053170. doi:10.2147/CCID.S137788Narrative review; the patient population studied in the cited trials was adults with acne vulgaris. Carries in this article only the depth classification (superficial, epidermis to papillary dermis; medium, papillary to upper reticular dermis; deep, mid-reticular dermis), the superficial agents the review listed (salicylic acid 5 to 30 percent, glycolic acid 30 to 50 percent, Jessner’s solution), TCA as superficial, medium or deep by concentration, and phenol as a deep peeling agent. Disclosure: the authors reported no conflicts.
- 5.Garelick E, Pohani P, Aswani A, Khan S, Chadha S, Patel T, Kebbe MB. Chemical Peels in Skin of Color: A Scoping Review of Safety, Efficacy, and Practice Patterns. Cureus. 2026;18(5):e108851. PMID 42306365. PMC13266789. doi:10.7759/cureus.108851Scoping review; 473 records screened, seven studies in Fitzpatrick types IV to VI included. Carries in this article: the three depth categories, the caution the authors advised with medium-to-deep peels in higher Fitzpatrick types, the authors’ observation that peeling and redness after a chemical peel can last a few weeks before subsiding, depending on strength and ingredients, and their finding that the evidence is limited by small samples, short follow-up and underrepresentation of types IV to VI. Disclosure: no financial support declared.
- 6.Santhanam U, Emmetsberger J, Nole G, Ortiz A, Gold M, Saliou C. A Topical Formulation Containing Macrocystis Pyrifera Ferment for Managing Barrier Damage After Mild-Moderate Skin Disruption from Cosmetic Dermatologic Procedures. J Clin Aesthet Dermatol. 2025;18(1):40-45. PMID 39830829. PMC11741175Two whole-face and three split-face randomized controlled clinical studies in women aged 31 to 65, including an in-clinic 70 percent glycolic acid peel. Carries in this article: that barrier disruption and recovery after a superficial glycolic peel were measured by transepidermal water loss, which shows the barrier change after a superficial peel can be quantified in a clinic setting. Disclosure: three authors are employees of the company that makes the serum and the others have served as its consultants or advisors; the authors noted limited sites and sample sizes.
- 7.Cameli N, Mariano M, Ardigò M, Corato C, De Paoli G, Berardesca E. Comparative instrumental evaluation of efficacy and safety between a binary and a ternary system in chemexfoliation. J Cosmet Dermatol. 2018;17(5):788-796. PMID 28940586. doi:10.1111/jocd.12424Comparative instrumental study on the volar forearm of 20 volunteers, testing pyruvic acid and TCA in two vehicle systems. Carries in this article: the measurement schedule (baseline, 10 minutes, 24 hours and 1 week) and the instruments (reflectance confocal microscopy of the stratum corneum, transepidermal water loss, corneometry, laser Doppler and colorimetry), and the authors’ report that the vehicle changed barrier alteration and water loss at the same acid concentration. Disclosure: two authors list a company affiliation, and the article evaluated a new formulation; funding not stated in the PubMed record.
- 8.Tijani AO, Frempong D, Kaur J, Sergent S, Shaw K, Lessaint R, Al Shawi M, Verana G, Puri A. Dermaplaning for Transdermal Drug Permeation Enhancement: A Qualitative and Quantitative Assessment. AAPS PharmSciTech. 2023;24(2):54. PMID 36725790. doi:10.1208/s12249-023-02505-yIn vitro laboratory study with histology, electrical resistance and permeation of two model drugs (baclofen and diclofenac) after four strokes of a dermaplane device, with several operators. Carries in this article: histology showing removal of the stratum corneum and some viable epidermis, a significant drop in electrical resistance, raised permeation over 24 hours, and variation between operators. Disclosure: academic authors; no industry funding in the PubMed record.
- 9.Tijani AO, Dandekar AA, Karve T, Banga AK, Puri A. Transdermal delivery of naloxone hydrochloride using minimally invasive physical ablation techniques. Int J Pharm. 2023;642:123159. PMID 37336303. doi:10.1016/j.ijpharm.2023.123159In vitro permeation study comparing sonophoresis, laser, dermaplaning, microneedles and microdermabrasion for a small hydrophilic molecule. Carries in this article: all techniques shortened the lag time to about 3 to 12 minutes from about 71 minutes for passive delivery, and in the first hour dermaplaning delivered less than sonophoresis or laser (about 31 against 83 and 1,278 micrograms per square centimeter). Disclosure: the authors declared no competing interests.
- 10.Pryor L, Gordon CR, Swanson EW, Reish RG, Horton-Beeman K, Cohen SR. Dermaplaning, topical oxygen, and photodynamic therapy: a systematic review of the literature. Aesthetic Plast Surg. 2011;35(6):1151-1159. PMID 21533984. doi:10.1007/s00266-011-9730-zSystematic review, PubMed search of August 2009, 42 peer-reviewed manuscripts across three procedures. Carries in this article: the authors’ conclusion that the scientific data supporting dermaplaning were scarce, anecdotal and not well documented, and their call for critical investigation. Disclosure: none stated in the PubMed record.
- 11.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized split-face trial over 12 weeks; 25 Korean adults with atrophic acne scars, Fitzpatrick III to IV; three sessions of a 10,600 nm fractional CO2 laser. Carries in this article only as the nearest controlled human study after a barrier-disrupting resurfacing procedure: the gel was applied just after each session and again over the following two days, patients rated erythema, swelling and dryness daily for seven days after each session, and the trial reported milder erythema and shorter downtime on the exosome side, with the vesicles characterized by particle tracking, cryo-electron microscopy and CD9, CD63 and CD81 markers. Disclosure: the exosome and control solutions were manufactured, purified and provided by the material’s manufacturer; the authors declared no conflicts.
- 12.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk of bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the review reported that most studies found improvement in at least one skin quality outcome and no serious adverse events, with risk of bias moderate to critical and GRADE certainty low or very low. Disclosure: academic authors (Canada); no conflict statement in the PubMed record.
- 13.Lin TJ, Huang YL, Kang YN, Chen C. Effectiveness of Topical Conditioned Medium of Stem Cells in Facial Skin Nonsurgical Resurfacing Modalities for Antiaging: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aesthetic Plast Surg. 2023;47(2):799-807. PMID 36396862. doi:10.1007/s00266-022-03168-zSystematic review and meta-analysis of randomized controlled trials, Cochrane risk-of-bias tool version 2; five trials included, four pooled. Carries in this article: the review’s scope named laser, chemical peeling and microneedling as resurfacing modalities, and it studied stem cell conditioned medium, a different material class from isolated vesicles; the abstract does not say how many included trials used a peel. Disclosure: academic authors; none stated in the PubMed record.
- 14.Zhang B, Lai RC, Sim WK, Tan TT, Lim SK. An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy. Biomolecules. 2024;14(6):622. PMID 38927026. PMC11202284. doi:10.3390/biom14060622Preclinical study in a mouse model of bleomycin-induced skin fibrosis (scleroderma model), with skin explant cultures. Carries in this article: fluorescence-labeled small vesicles applied topically to skin explants localized in the stratum corneum, and the authors reported more than 100 proteins shared between the stratum corneum and the vesicles. Disclosure: all five authors were employed by a company developing vesicle products, and one is its founder and director.
- 15.Choi BY, Kim HJ, Kim MJ, Roh YJ, Hong JY, Park KY, Sul WJ. Adipose tissue-derived stem cell exosomes enhance skin barrier function and show exploratory associations with the skin mycobiome in aging skin. J Microbiol. 2026;64(6):e2603020. PMID 42403177. PMC13577115. doi:10.71150/jm.2603020Split-face randomized controlled trial in 16 adults aged 40 and over; ultrasound-assisted delivery of an adipose stem cell exosome solution on one side and saline on the other, three sessions two weeks apart, on skin with no peel. Carries in this article: the authors reported lower transepidermal water loss on the exosome side at weeks 2 and 8 and no significant adverse events. Disclosure: the material’s manufacturer supplied it and funded the study.
- 16.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline. Carries in this article: the reference headings (separation from non-vesicular particles, size, concentration, marker proteins, morphology) that a certificate of analysis can be read against. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
- 17.Lardieri A, Reyes M, Konkel KE, Diak IL, McCulley L. Skin Injuries Following Layperson Application of Chemical Peel Products. J Clin Aesthet Dermatol. 2025;18(11):41-43. PMID 41446714. PMC12724979Case series from the FDA Center for Drug Evaluation and Research, drawing on the FDA Adverse Event Reporting System, the Human Foods Complaint System, the literature and consumer product reviews, August 2018 to August 2023. Carries in this article: the authors identified 18 skin injuries after layperson application of chemical peel products, several with products labeled at concentrations typically used by healthcare professionals; the authors concluded that laypeople applying these products without guidance from licensed, trained professionals may experience skin injury, and noted underreporting as a limitation. Disclosure: the authors reported no relevant conflicts.
- 18.U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of 11 September 2024 (verified 9 November 2026). https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soapAgency guidance page (FDA cosmetics program). Carries in this article: the agency position that intended use, established by labeling, advertising, online and promotional claims, decides whether a product is a cosmetic, a drug or both, and that claims to affect the structure or function of the body, such as claims to regenerate cells, make a product a drug.
- 19.U.S. Food and Drug Administration. Alpha Hydroxy Acids. Content current as of 22 November 2022 (verified 9 November 2026). https://www.fda.gov/cosmetics/cosmetic-ingredients/alpha-hydroxy-acidsAgency ingredient page. Carries in this article: the agency description of products marketed as skin peelers, which may contain relatively high acid concentrations designed to remove the outer layer of skin; its count of 114 adverse dermatologic reports for AHA skin care products from 1992 to February 2004, with the more serious reactions most often reported for the products causing the greatest exfoliation; and the FDA research reporting an 18 percent rise in sensitivity to UV-induced reddening after four weeks of an AHA cream, with no significant difference in UV sensitivity one week after use stopped.
- 20.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, with MedWatch named as the reporting route for adverse events.